These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 31866454)

  • 1. Molecular targets and therapeutic interventions for iron induced neurodegeneration.
    Bagwe-Parab S; Kaur G
    Brain Res Bull; 2020 Mar; 156():1-9. PubMed ID: 31866454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A combination of an iron chelator with an antioxidant effectively diminishes the dendritic loss, tau-hyperphosphorylation, amyloids-β accumulation and brain mitochondrial dynamic disruption in rats with chronic iron-overload.
    Sripetchwandee J; Wongjaikam S; Krintratun W; Chattipakorn N; Chattipakorn SC
    Neuroscience; 2016 Sep; 332():191-202. PubMed ID: 27403880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurodegenerative diseases and therapeutic strategies using iron chelators.
    Ward RJ; Dexter DT; Crichton RR
    J Trace Elem Med Biol; 2015; 31():267-73. PubMed ID: 25716300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mini-Review: Is iron-mediated cell death (ferroptosis) an identical factor contributing to the pathogenesis of some neurodegenerative diseases?
    Viktorinova A; Durfinova M
    Neurosci Lett; 2021 Feb; 745():135627. PubMed ID: 33440237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ferroptosis as a mechanism of neurodegeneration in Alzheimer's disease.
    Jakaria M; Belaidi AA; Bush AI; Ayton S
    J Neurochem; 2021 Dec; 159(5):804-825. PubMed ID: 34553778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review on iron chelators as potential therapeutic agents for the treatment of Alzheimer's and Parkinson's diseases.
    Singh YP; Pandey A; Vishwakarma S; Modi G
    Mol Divers; 2019 May; 23(2):509-526. PubMed ID: 30293116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of antioxidants and iron chelators in the treatment of oxidative stress in thalassemia.
    Fibach E; Rachmilewitz EA
    Ann N Y Acad Sci; 2010 Aug; 1202():10-6. PubMed ID: 20712766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iron chelating strategies in systemic metal overload, neurodegeneration and cancer.
    Gumienna-Kontecka E; Pyrkosz-Bulska M; Szebesczyk A; Ostrowska M
    Curr Med Chem; 2014; 21(33):3741-67. PubMed ID: 25005181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iron overload cardiomyopathy: Using the latest evidence to inform future applications.
    Kumfu S; Chattipakorn SC; Chattipakorn N
    Exp Biol Med (Maywood); 2022 Apr; 247(7):574-583. PubMed ID: 35130741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Striking while the iron is hot: Iron metabolism and ferroptosis in neurodegeneration.
    Masaldan S; Bush AI; Devos D; Rolland AS; Moreau C
    Free Radic Biol Med; 2019 Mar; 133():221-233. PubMed ID: 30266679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iron in neurodegenerative disorders: being in the wrong place at the wrong time?
    Apostolakis S; Kypraiou AM
    Rev Neurosci; 2017 Nov; 28(8):893-911. PubMed ID: 28792913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic applications of chelating drugs in iron metabolic disorders of the brain and retina.
    Shahandeh A; Bui BV; Finkelstein DI; Nguyen CTO
    J Neurosci Res; 2020 Oct; 98(10):1889-1904. PubMed ID: 32643793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Iron and Ferroptosis More than a Suspect: Beyond the Most Common Mechanisms of Neurodegeneration for New Therapeutic Approaches to Cognitive Decline and Dementia.
    Cerasuolo M; Di Meo I; Auriemma MC; Trojsi F; Maiorino MI; Cirillo M; Esposito F; Polito R; Colangelo AM; Paolisso G; Papa M; Rizzo MR
    Int J Mol Sci; 2023 Jun; 24(11):. PubMed ID: 37298586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of iron overload syndrome: a general review.
    Lima TG; Benevides FLN; Esmeraldo Filho FL; Farias IS; Dourado DXC; Fontenele EGP; Moraes MEA; Quidute ARP
    Rev Assoc Med Bras (1992); 2019; 65(9):1216-1222. PubMed ID: 31618341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of iron in brain ageing and neurodegenerative disorders.
    Ward RJ; Zucca FA; Duyn JH; Crichton RR; Zecca L
    Lancet Neurol; 2014 Oct; 13(10):1045-60. PubMed ID: 25231526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanoparticle iron chelators: a new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance.
    Liu G; Men P; Harris PL; Rolston RK; Perry G; Smith MA
    Neurosci Lett; 2006 Oct; 406(3):189-93. PubMed ID: 16919875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease.
    Jellinger KA
    Drugs Aging; 1999 Feb; 14(2):115-40. PubMed ID: 10084365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain iron homeostasis: from molecular mechanisms to clinical significance and therapeutic opportunities.
    Singh N; Haldar S; Tripathi AK; Horback K; Wong J; Sharma D; Beserra A; Suda S; Anbalagan C; Dev S; Mukhopadhyay CK; Singh A
    Antioxid Redox Signal; 2014 Mar; 20(8):1324-63. PubMed ID: 23815406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Melatonin: Potential avenue for treating iron overload disorders.
    Yang J; Tang Q; Zeng Y
    Ageing Res Rev; 2022 Nov; 81():101717. PubMed ID: 35961513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined therapy of iron chelator and antioxidant completely restores brain dysfunction induced by iron toxicity.
    Sripetchwandee J; Pipatpiboon N; Chattipakorn N; Chattipakorn S
    PLoS One; 2014; 9(1):e85115. PubMed ID: 24400127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.